Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof

Abstract

The hepatitis C virus (HCV) is a global public health problem, with chronic infection leading to development of cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC).. Treatment of HCV is suboptimal with overall response rates of slightly greater than 50% when patients are treated with pegylated interferon alfa and ribavirin.. Thymosin alpha 1 (Talpha1; TA-1) is an.

Key Findings

Thymosin alpha 1 (Talpha1; TA-1) is an immunomodulatory peptide with intrinsic activities that might improve treatment outcomes for HCV by incorporation of this agent in current treatment paradigms. | However, clinical trials to date have failed to conclusively support the role of TA-1 in combination

Study Design

Clinical study